64.88 -0.03 (-0.05%)
After hours: 5:03PM EDT
|Bid||64.60 x 2200|
|Ask||64.98 x 4000|
|Day's Range||64.20 - 65.45|
|52 Week Range||60.32 - 74.80|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||14.07|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||2.52 (3.86%)|
|1y Target Est||79.97|
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
The typical Facebook employee stays with the company for just over 2.5 years, a Business Journal analysis shows. This is how that compares to other large Silicon Valley tech employers, like Cisco, Apple and Intel.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Gilead corporate development head Andy Dickinson’s elevation to CFO means that partnerships and acquisitions will be at the center of the company’s strategy, one analyst says.
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
Gilead Sciences Inc. said Tuesday it has appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Dickinson is currently executive vice president corporate development and strategy and will become a member of the senior leadership team reporting to Chief Executive Daniel O'Day. The executive joined the company in 2016 after stints at Lazard and Myogen Inc., which Gilead acquired in 20016. Shares were not yet active premarket, but have gained 3% in 2019, while the S&P 500 has gained 18%.
Gilead Sciences, Inc. (GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company’s Executive Vice President, Corporate Development and Strategy, and in his new role he will continue to be a member of the senior leadership team, reporting to Daniel O’Day, Chairman and Chief Executive Officer. Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making.
South San Francisco-based Allogene is taking a different approach to cell therapy for cancer by producing so-called allogenic cell therapies.
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences.
Gilead Sciences, Inc. (GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call.
The financial regulations require hedge funds and wealthy investors that crossed the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]